eCite Digital Repository
Controlling cancer pain: Is morphine the best we can do?
Citation
Dietis, ND and Rowbotham, DJ and Lambert, DG, Controlling cancer pain: Is morphine the best we can do?, Trends in anaesthesia and critical care, 1 pp. 227-229. ISSN 2210-8467 (2011) [Substantial Review]
 | PDF Not available 131Kb |
DOI: doi:10.1016/j.tacc.2011.08.003
Abstract
Despite the existence of a family of 3 classical and one non-classical opioid receptor, morphine, acting at
the MOP (m) receptor remains the gold standard for use in cancer pain. The main thrust of opioid
development has been to produce highly selective morphine like molecules but these produce side
effects (respiratory depression and arrest, constipation, nausea and vomiting, pruritis and tolerance).
Tolerance is particularly troublesome as this leads to increased dosing and more side effects. Laboratory
experiments suggest that simultaneous targeting of multiple members of the opioid family may be the
way forward. For example disruption of DOP (d) receptor activity reduces morphine tolerance. Rational
design and evaluation of non-selective opioids might offer good quality analgesia, reduced side effects
and an alternative to morphine.
Item Details
| Item Type: | Substantial Review |
|---|---|
| Keywords: | morphine |
| Research Division: | Biomedical and Clinical Sciences |
| Research Group: | Pharmacology and pharmaceutical sciences |
| Research Field: | Basic pharmacology |
| Objective Division: | Manufacturing |
| Objective Group: | Human pharmaceutical products |
| Objective Field: | Human pharmaceutical products not elsewhere classified |
| UTAS Author: | Dietis, ND (Dr Nikolas Dietis) |
| ID Code: | 80394 |
| Year Published: | 2011 |
| Deposited By: | Pharmacy |
| Deposited On: | 2012-10-31 |
| Last Modified: | 2015-05-15 |
| Downloads: | 0 |
Repository Staff Only: item control page